43 results
8-K
EX-10.1
ONCSQ
ONCOSEC MEDICAL Inc
18 May 23
OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:35pm
not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit
8-K
EX-10.1
ONCSQ
ONCOSEC MEDICAL Inc
11 Apr 23
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:05pm
not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit
424B3
ONCSQ
ONCOSEC MEDICAL Inc
1 Dec 22
Prospectus supplement
4:56pm
, including our competitors, that infringe our issued patents or other intellectual property rights. If we choose to file a lawsuit against a potentially … narrowing of claim scope under the current standards. Moreover, even if the validity of our patents is upheld in a patent infringement lawsuit, a court
8-K
EX-10.1
u4tr1j2z3oms 2crgko
16 Aug 21
Departure of Directors or Certain Officers
4:00pm
8-K
EX-10.1
2xq054qu0lv3u2shx
24 Jun 21
Departure of Directors or Certain Officers
4:55pm
DFAN14A
y3jgt67finpriibe jo
6 Dec 19
Additional proxy materials by non-management
4:08pm
DEFN14A
uh8w2lh
6 Dec 19
Definitive proxy statement filed by non-management
9:52am
DFAN14A
kln6hojk5qh0pu
5 Dec 19
Additional proxy materials by non-management
4:03pm
PRRN14A
ub6y1dku9js89b 7mu0s
4 Dec 19
Revised preliminary proxy statement filed by non-management
5:26pm
PRRN14A
slmrmf2
3 Dec 19
Revised preliminary proxy statement filed by non-management
10:00am
DEFA14A
p7m93y6sun7 h8ur
2 Dec 19
Additional proxy soliciting materials
8:36am
DEFA14A
rn69n
2 Dec 19
Additional proxy soliciting materials
8:13am